Management of Type 2 Diabetes with HbA1c 7.8%

Treatment Rationale

For patients with type 2 diabetes and HbA1c of 7.8%, a target HbA1c of <7% is appropriate to reduce the risk of microvascular and macrovascular complications, as recommended by the American College of Physicians, based on evidence from the Annals of Internal Medicine 1, 2, 3
Combination therapy is often more effective than monotherapy when HbA1c is >7.5%, making Janumet XR (sitagliptin/metformin combination) a rational choice, according to the American Diabetes Association, as published in Diabetes Care 4
Metformin remains the cornerstone first-line therapy for type 2 diabetes due to its efficacy, safety profile, and low cost, as stated by the American Association of Clinical Endocrinologists, based on evidence from Diabetes Care 5

Regular monitoring of HbA1c every 3-6 months is recommended to assess treatment efficacy, as advised by the American Diabetes Association, based on evidence from the Annals of Internal Medicine and Diabetes Care 1, 6
If HbA1c target is not achieved within 3-6 months, treatment intensification should be considered, according to the American College of Physicians, as published in Diabetes Care 4

Janumet XR represents a cost-effective option compared to newer agents like GLP-1 receptor agonists or SGLT2 inhibitors, as mentioned in Diabetes Care, and is a consideration for patients with type 2 diabetes, as recommended by the American Association of Clinical Endocrinologists 4